No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Editor: What To Know

  • When defining and laying the groundwork for this position and hire, it was paramount that we employ someone with exceptional personal and professional relationships in oncology, significant knowledge in the particle therapy space and most important, a well thought of leader, with a high moral and ethical compass.
  • I’m also excited to bring over 23 years of proton therapy and radiation oncology experience and knowledge which will assist our current and future clinical partners with solutions for the delivery of this this innovative and lifesaving technology both domestically and internationally,”.
  • Jon Hopkins brings to Legion more than 25 years of experience in healthcare, primarily in radiation oncology hardware, software, education, training, strategic planning, and execution.

Jon Hopkins brings to Legion more than 25 years of experience in healthcare, primarily in radiation oncology hardware, software, education, training, strategic planning, and execution.

“Partnering with large medical systems to bring lifesaving, proton therapy treatment options to thousands of patients around the US is our core mission. When defining and laying the groundwork for this position and hire, it was paramount that we employ someone with exceptional personal and professional relationships in oncology, significant knowledge in the particle therapy space and most important, a well thought of leader, with a high moral and ethical compass. We are thrilled to have Jon’s fresh vision, energy and experience to help meet Legion’s mission of supporting those who need cancer care and those who provide that care,” said John Styles, Legion’s Chairman and Chief Executive Officer.

Over the past 23 years, Jon Hopkins has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy. Jon Hopkins has provided leadership, sales and or support to over 17 proton therapy centers both domestically and internationally.

“I am thrilled to join the extraordinary team at Legion Healthcare Partners. It’s truly a wonderful opportunity to make a real difference, working alongside colleagues I’ve known, both personally and professionally for decades. I’m also excited to bring over 23 years of proton therapy and radiation oncology experience and knowledge which will assist our current and future clinical partners with solutions for the delivery of this this innovative and lifesaving technology both domestically and internationally,” says Mr. Hopkins.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy